Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jamie Spence

Clinical Nurse Specialist, Adult Health Ardmore, OK Nurse Practitioner

NPI 1861845190 CMS profile 10700431

731 12Th Ave Nw Ste 302, Ste 302, Ardmore, OK 73401

Open in the dashboard

General payments

$3,274

140 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jamie Spence of Ardmore, OK is reported in the CMS Open Payments database as having received $3,274 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $444 28
2024 General $1,064 24
2023 General $538 31
2022 General $526 27
2021 General $702 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamie Spence
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Jamie Spence were reported at $444. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Jamie Spence Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $702 $133 $48–$445 $132
2022 $526 $163 $57–$526 $149
2023 $538 $173 $64–$597 $160
2024 $1,064 $171 $54–$575 $164
2025 $444 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $731 61 payments
  2. Boston Scientific Corporation $530 6 payments
  3. Vertos Medical, Inc. $342 4 payments
  4. Spinal Simplicity, LLC $195 2 payments
  5. Nevro Corp. $195 4 payments
  6. Averitas Pharma Inc. $153 7 payments
  7. AbbVie, Inc. $147 6 payments
  8. GRT US Holding, Inc. $122 7 payments
  9. SPR Therapeutics, Inc $119 4 payments
  10. Saluda Medical Americas, Inc. $96 5 payments
  11. Other $643 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,068 139 payments
  2. Travel and Lodging $206 1 payment
Products named General payments · program years 2021–2025
  1. Intracept $549 6 payments
  2. mild Device Kit $342 4 payments
  3. Qutenza $276 14 payments
  4. PROCLAIM Neuromodulation $203 20 payments
  5. HA MINUTEMAN G3-R $195 2 payments
  6. PROCLAIM Neuromodulation $157 9 payments
  7. Senza $153 2 payments
  8. SPRINT PNS System $119 4 payments
  9. Evoke $96 5 payments
  10. PROCLAIM Structural Heart $92 6 payments
  11. Other $1,326 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,209

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$18,168

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

0%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 520 $10,500
Celecoxib Generic 97 $1,822
Tizanidine Hcl Generic 127 $1,356
Baclofen Generic 98 $1,188
Meloxicam Generic 150 $976
Methocarbamol Generic 35 $620
Cyclobenzaprine Hcl Generic 77 $530
Diclofenac Sodium Generic 38 $392
Duloxetine Hcl Generic 20 $296
Nortriptyline Hcl Generic 32 $279

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$111,627

Of which drugs: $11,177

Medicare patients

733

Average age 74

Services billed

5,638

442 women, 291 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Diabetes 34%
Chronic kidney disease 31%
Depression 31%
COPD 24%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $57
$57 — —
Qutenza
  • Averitas Pharma Inc. $26
$26 — —
BOTOX
  • AbbVie, Inc. $20
$20 — —
UBRELVY
  • AbbVie, Inc. $13
$13 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record